乌司他丁联合醒脑静注射液治疗重度颅脑损伤的临床观察

Clinical Observation on Ulinastatin Combined with Xingnaojing Injection in the Treatment of Severe Craniocerebral Injury

目的:探讨乌司他丁联合醒脑静注射液治疗重度颅脑损伤的临床效果。方法:分析我院2015年1月—2017年12月收治的122例重度颅脑损伤患者的临床资料,按照治疗方案的不同分为两组,对照组60例给予乌司他丁(20万单位加入50 mL 0.9%氯化钠注射液中静脉滴注,bid)治疗,观察组62例给予乌司他丁(同对照组)联合醒脑静注射液(20 mL加入250 mL 10%葡萄糖注射液中静脉滴注,qd)治疗。比较两组血清学指标变化情况、格拉斯哥昏迷(GCS)评分、临床疗效及不良反应发生情况。结果:治疗后观察组神经元特异性烯醇化酶(NSE)、S100B蛋白水平显著低于对照组,GCS评分高于对照组,差异有统计学意义(P <0.05);观察组临床疗效优于对照组,差异有统计学意义(Z=-4.239,P <0.05);两组不良反应发生率比较,差异无统计学意义(P> 0.05)。结论:乌司他丁联合醒脑静注射液治疗重度颅脑损伤能显著降低患者血清NSE、S100B水平,改善昏迷状况,提高治疗效果。

Objective:To investigate the clinical effect of ulinastatin combined with xingnaojing injection in the treatment of severe craniocerebral injury.Methods:The clinical data of 122 patients with severe craniocerebral injury admitted to our hospital from January 2015 to December 2017 were analyzed and divided into two groups according to different treatment regimens.60 patients in the control group were treated with ulinastatin(200,000 units were added to 50 mL 0.9%sodium chloride injection,intravenous drip,bid),and 62 patients in the observation group were treated with ulinastatin(the same as control group)combined with xingnaojing injection(20 mL drug was added to 250 mL 10%glucose injection,intravenous drip,qd).The changes in serological indexes,Glasgow coma scale(GCS)scores,clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,the levels of neuron-specific enolase(NSE)and S100B protein in the observation group were significantly lower than those in the control group,and the GCS scores were higher than those in the control group,with statistically significant differences(P<0.05).The clinical efficacy in the observation group was better than that in the control group,and the difference was statistically significant(Z=-4.239,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Ulinastatin combined with xingnaojing injection can significantly reduce the levels of serum NSE and S100B in patients with severe craniocerebral injury,improve coma and improve the therapeutic effect.